• Dyne Therapeutics director Jason P. Rhodes reported sales of 2,586,928 common shares on Aug. 13-14.
• Sales priced at USD 26.2 on Aug. 13, USD 25 on Aug. 14.
• Holdings reported indirectly fell to 2,962 shares following the transactions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dyne Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001577014-26-000016), on August 17, 2026, and is solely responsible for the information contained therein.